Abbott Laboratories
NYSE:ABT
Abbott Laboratories
NYSE:ABT
Price:
105.27 USD
-0.59%
Market Closed
Updated:
Apr 19, 2024
Abbott Laboratories
Cash from Financing Activities
Last
Value
3-Years CAGR
5-Years CAGR
|
Abbott Laboratories
Cash from Financing Activities Peer Comparison
Comparables:
BDX
BSX
EW
SYK
ISRG
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Abbott Laboratories
NYSE:ABT
|
Cash from Financing Activities
$-7.1B
|
CAGR 3-Years
-37%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-1%
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Cash from Financing Activities
$-2.3B
|
CAGR 3-Years
-144%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-10%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Cash from Financing Activities
$5m
|
CAGR 3-Years
-74%
|
CAGR 5-Years
-68%
|
CAGR 10-Years
N/A
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Cash from Financing Activities
$-711m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Stryker Corp
NYSE:SYK
|
Cash from Financing Activities
$-1.6B
|
CAGR 3-Years
-425%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Cash from Financing Activities
$-287.6m
|
CAGR 3-Years
-50%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
11%
|
See Also
What is Abbott Laboratories's Cash from Financing Activities?
Cash from Financing Activities
-7.1B
USD
-7.1B
USD
Based on the financial report for Dec 31, 2023, Abbott Laboratories's Cash from Financing Activities amounts to -7.1B USD.
What is Abbott Laboratories's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
-1%
-1%
Over the last year, the Cash from Financing Activities growth was 7%. The average annual Cash from Financing Activities growth rates for Abbott Laboratories have been -37% over the past three years , 7% over the past five years , and -1% over the past ten years .
You don't have any saved screeners yet
